Director at Seaport Therapeutics (SPTX) awarded 12,258 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Seaport Therapeutics, Inc. director David E. Wheadon received a grant of stock options covering 12,258 shares of common stock. The options have an exercise price of $18.00 per share and expire on April 29, 2036. All 12,258 underlying shares vest in full on April 30, 2027, subject to his continued service, and this grant represents his entire reported option position in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wheadon David E.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	12,258	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 12,258 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 12,258 options Exercise price: $18.00 per share Underlying shares: 12,258 shares +3 more

6 metrics

Option grant size 12,258 options Grant to director David E. Wheadon

Exercise price $18.00 per share Stock option strike price

Underlying shares 12,258 shares Common stock underlying the options

Expiration date April 29, 2036 Option term end

Vesting date April 30, 2027 Full vesting if service continues

Holdings after grant 12,258 options Total derivative holdings following transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 18.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-04-29T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"shall vest in full on April 30, 2027, subject to the Reporting Person's continued service"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

05/04/2026 - 06:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wheadon David E.

(Last)

(First)

(Middle)

SEAPORT THERAPEUTICS, INC.

101 SEAPORT BLVD., FLOOR 12

(Street)

BOSTON

MASSACHUSETTS

02210

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Seaport Therapeutics, Inc. [ SPTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$18	04/30/2026		A		12,258		⁽¹⁾	04/29/2036	Common Stock	12,258	$0	12,258	D

Explanation of Responses:

1. The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date.

	/s/ Lana Gladstein, Attorney-in-Fact	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Seaport Therapeutics (SPTX) director David E. Wheadon report on this Form 4?

David E. Wheadon reported receiving a stock option grant for 12,258 shares of Seaport Therapeutics common stock, exercisable at $18.00 per share. The filing reflects a compensation-related award rather than an open-market purchase or sale of shares.

How many Seaport Therapeutics (SPTX) shares are covered by the new option grant?

The option grant covers 12,258 shares of Seaport Therapeutics common stock. These options give the director the right to buy that number of shares at a fixed $18.00 exercise price before the stated expiration date.

What is the exercise price and expiration date of the Seaport Therapeutics (SPTX) options?

The options have an exercise price of $18.00 per share and expire on April 29, 2036. This means the director can choose to buy shares at $18.00 any time before that expiration date, once the options are vested.

When do David E. Wheadon’s Seaport Therapeutics (SPTX) options vest?

All 12,258 shares underlying the option grant vest in full on April 30, 2027. Vesting is conditioned on the director’s continued service with Seaport Therapeutics through that vesting date, according to the disclosed footnote.

Is this Seaport Therapeutics (SPTX) Form 4 a market buy or sell of shares?

No, this Form 4 reflects a grant or award acquisition of stock options, not an open-market trade. The transaction is coded “A,” indicating a compensation-related grant rather than a purchase or sale in the public market.